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Abstract
Background Patients with severe hemophilia A (SHA) in Italy are routinely treated with standard half-life recombinant factor 
VIII (rFVIII) products. rFVIII Fc-fusion protein (rFVIIIFc) is an extended half-life rFVIII product that enables less frequent 
administration than rFVIII, which may support improved adherence. Available data indicate low breakthrough bleed rates 
and potentially improved long-term joint health for patients treated with rFVIIIFc prophylaxis.
Objective This study assessed the cost effectiveness of rFVIIIFc versus rFVIII from an Italian healthcare perspective.
Methods A Semi-Markov model was constructed to assess the lifetime costs and benefits of rFVIII and rFVIIIFc prophylaxis. 
rFVIII product acquisition costs from a published Italian database were included for both prophylaxis and the resolution of 
breakthrough bleeding. Clinical outcomes within the model were determined based on published annualized bleeding rates 
and literature regarding the development of target joints (TJs) as the incidence of bleeds and TJs is associated with impaired 
health-related quality of life. Cost effectiveness was assessed using cost per quality-adjusted life-year (QALY) gained.
Results Compared with rFVIII, rFVIIIFc was associated with a per-patient cost saving of approximately €1.3 million and 
QALY gains of 0.39 over a lifetime horizon. Sensitivity analyses considering alternative efficacy, dosing, and structural 
assumptions each showed that rFVIIIFc dominated rFVIII (i.e., provided more QALYs at a reduced cost).
Conclusions This cost-effectiveness analysis demonstrated that rFVIIIFc may offer a cost-effective treatment option for 
patients with SHA in Italy.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4166 9-019-0158-8) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Hemophilia A (HA), caused by an inherited deficiency of 
factor VIII (FVIII), is the most common type of hemo-
philia, with an incidence of 1 in 5000 male births [1]. 
Patients with HA are at risk of life-threatening bleeding, 
particularly patients with severe disease (defined as endog-
enous factor VIII coagulant activity [FVIII:C] level < 1% 
of the normal amount), which accounts for approximately 
46.2% of Italian cases [2]. More commonly, patients expe-
rience bleeding into joints (hemarthroses) and muscles, 
which can be severely debilitating [3, 4].
Key Points for Decision Makers 
Prophylaxis with recombinant Factor VIII (rFVIII) is 
the recognized standard of care in severe hemophilia 
A. However, management with conventional rFVIII 
therapies requires frequent infusions to maintain trough 
levels > 1% to prevent bleeds and joint damage. Factor 
consumption remains the major contributor to cost in the 
management of hemophilia.
rFVIII Fc fusion protein (rFVIIIFc), with its extended 
half-life, provides cost savings and improved health-
related quality of life compared with conventional rFVIII 
therapies, based on improved joint health and lower 
annualized bleed rates.
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of these data permit an assessment of factor consumption 
within a real-life setting.
This study aims to assess the cost effectiveness of rFVII-
IFc versus SHL rFVIII for the prophylaxis treatment of SHA 
patients from an Italian healthcare perspective. This analysis 
makes use of recently published data regarding joint health 
and real-world usage of rFVIII products and thus provides an 
estimate of the cost effectiveness of rFVIIIFc versus rFVIII 
in Italian practice.
2  Methods
2.1  Model Structure
The model used to inform this cost-effectiveness analysis 
(CEA) built on the structure previously adopted by Henry 
et al. [22], who assessed the cost effectiveness of rFVIIIFc 
versus conventional rFVIII for Swedish SHA patients. Henry 
et al. [22] did not explicitly model the impact of treatment 
on joint health because published evidence was lacking, par-
ticularly for the Pettersson score, which is a scoring system 
used to reflect the extent of hemophilic arthropathy (perma-
nent joint damage caused by hemophilia-related bleeding) 
and is widely used in hemophilia clinical trials [22, 23]. 
Without this evidence, it would not be possible to link the 
measured joint damage to patient-related outcomes.
While evidence concerning the relationship between 
patient utility and the Pettersson score remains limited, a 
study by O’Hara et al. [5] facilitated the specification of a 
CEA with health states according to TJ status. Other stud-
ies in SHA have also captured joint health, but these were 
primarily constructed to correspond with the availability of 
patient data. We considered the model structures employed 
within these previous studies but ultimately rejected them 
because of the lack of comparably robust data for rFVIII 
and rFVIIIFc.
The definition of a TJ has changed over time and typi-
cally refers to the frequent occurrence of bleeding into a 
given joint within a relatively short time [24, 25]. However, 
the definition of a TJ accepted by the International Society 
on Thrombosis and Hemostasis is a single joint into which 
three or more spontaneous bleeds occur within a consecu-
tive 6-month period [26]. Patients may develop multiple TJs 
in different sites, the most common of which are the knee, 
ankle, or elbow [24, 27]. Data regarding the incidence and/or 
resolution of TJs are now routinely collected in SHA clinical 
studies, the latter of which is particularly important given 
the treatment goals of HA being the prevention of bleeding 
and joint destruction to preserve normal musculoskeletal 
function [25].
We constructed a three-state semi-Markov model in 
 Microsoft® Excel (overview shown in Fig. 1). Upon model 
Hemarthroses and bleeding into muscles can result 
in the development of arthropathy (disease of the joint), 
which is associated with swelling, pain, and reduced 
movement [4]. Repeated hemarthroses in the same loca-
tion leads to increased medical resource use and impaired 
patient health-related quality of life (HRQoL) [5]. As such, 
the primary treatment goals for patients with severe HA 
(SHA) pertain to the reduction of bleeding events and the 
prevention of joint health deterioration.
In Italy, the treatment of SHA most commonly involves 
routine prophylaxis using recombinant FVIII (rFVIII) 
replacement products as well as episodic rFVIII treatment 
for the resolution of breakthrough bleeds. Published litera-
ture suggests that 90–92% of total direct healthcare costs 
associated with HA patients are attributable to drug acqui-
sition [6, 7]. Most adult Italian SHA patients are treated 
with rFVIII prophylaxis, and nearly all pediatric patients 
are expected to be treated prophylactically [2].
Compared with on-demand use only (i.e., used only 
for the resolution of a breakthrough bleed), prophylaxis 
with standard half-life (SHL) rFVIII treatment has been 
shown to significantly reduce the annualized bleeding rate 
(ABR) for SHA patients [8–13]. The most commonly used 
rFVIII product for prophylaxis treatment in Italian practice 
is  Advate® (Shire Pharmaceuticals Ltd) [2, 14].
Extended half-life (EHL) FVIII Fc fusion protein 
(rFVIIIFc,  Elocta®, Swedish Orphan Biovitrum AB) offers 
an alternative rFVIII treatment option. Its EHL means that 
patients treated at the same frequency and dose as those 
using SHL rFVIII products are expected to spend less time 
below a given targeted trough level (endogenous FVIII:C 
level) such that the risk of experiencing breakthrough 
bleeds is reduced [15, 16]. Alternatively, the EHL of rFVI-
IIFc may permit a reduction in administration frequency 
versus conventional factor therapies and consequently 
reduce treatment burden, which may also increase adher-
ence to treatment and improve HRQoL [17]. rFVIIIFc 
prophylaxis has been studied in both adult and pediatric 
populations and has been shown to be associated with low 
ABRs as well as improved joint health outcomes (deter-
mined via the modified Hemophilia Joint Health Score 
[mHJHS]) over time [18–20].
Until recently, data regarding the association between 
joint health and patient HRQoL in patients with SHA were 
limited. In 2018, O’Hara et al. [5] published a study that 
provided information regarding the difference in utility 
between patients with and without “target joints” (TJs), and 
von Mackensen et al. [21] demonstrated the relationship 
between improved joint health (measured with the mHJHS) 
and HRQoL (measured using the EuroQoL 5-Dimensions 
[EQ-5D] and the Haem-A-QoL questionnaires). In addition, 
data are now available on the real-world usage of SHL and 
EHL rFVIII products in the prophylactic setting. Analysis 
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entry, patients are categorized by TJ status (i.e., whether 
they had at least one TJ). Transitions between the “alive” TJ-
related health states were determined according to calculated 
rates of TJ development or resolution, whereas transitions 
to death were based on background mortality rates (which 
are age dependent). The impact of each treatment on patient 
HRQoL was determined according to the ABR (to determine 
the impact of a bleed event) and the presence of TJs. The 
costs considered by the model are related only to Factor 
consumption (both as prophylaxis and for the resolution of 
breakthrough bleeding).
In this analysis, we did not consider the probability of 
developing inhibitors for patients treated with either rFVIII 
or rFVIIIFc. No clear evidence exists of a differential risk 
of inhibitor development by prophylaxis regimen, so the 
inclusion of inhibitor development would be unlikely to 
affect the overall conclusions that may be made from the 
analysis.
Guidelines for the pharmacoeconomic evaluation of new 
drugs in Italy were reported by Capri et al. [28]. They rec-
ommend the presentation of outcomes in terms of costs and 
quality-adjusted life-years (QALYs), annual discount rates 
for these outcomes of 3.0%, and limiting to 30 years the time 
horizon over which these outcomes are considered [28]. We 
applied annual discount rates of 3.0% for both costs and 
QALYs but considered a lifetime horizon in the model base 
case (up to 99 years) as patients are treated with prophylaxis 
indefinitely (and are assumed to enter the model at the age 
of 1 year). While restricting the time horizon to 30 years 
would omit important costs and outcomes from the analysis, 
alternative time horizons were explored within sensitivity 
analysis. A model cycle length of 1 year was used, and—
based on published guidance—a half-cycle correction was 
applied because the probability of leaving a given health 
state was > 5% (and the model cycle length is > 2 weeks) 
[29, 30].
The CEA adopts the perspective of the Italian national 
health service. The population considered is that of Italian 
patients with SHA, for which rFVIII prophylaxis represents 
the standard of care. In Italy, the most commonly used SHL 
rFVIII is Advate, hence a comparison between prophylaxis 
regimens with rFVIII (for which Advate is assumed to be 
representative of Italian practice) and rFVIIIFc is presented 
[2]. Use of rFVIII to resolve breakthrough bleeding episodes 
is also included within the analysis because, in the event of 
a bleed, the condition is controlled with rFVIII.
2.2  Model Inputs
2.2.1  Efficacy
Treatment efficacy was considered in two categories: (1) 
the impact of treatment on the number of bleeding episodes 
(measured with the ABR)—“bleeding-related outcomes” 
and (2) the impact of treatment on joint health—“joint-
related outcomes”. Bleeding-related outcomes are well 
reported in published literature for each treatment, as the 
ABR is often the primary outcome of clinical trials in HA. 
However, joint-related outcomes are less reported, so we 
undertook a literature search to address data gaps.
We used published ABRs to determine the number of 
bleeds for patients treated with rFVIII and rFVIIIFc per 
model cycle (1 year), and these were subsequently used 
to determine the number of QALYs lost as a result of 
bleeding. The ABRs used for adult and pediatric patients 
receiving rFVIII and rFVIIIFc are summarized in Table 1 
and were taken from the A-LONG, Kids A-LONG, and 
rAHF-PFM clinical trials (NCT01181128, NCT01458106, 
NCT00243386, NCT00157040) [19, 20, 31, 32]. We found 
no trials that provided direct comparisons between rFVIII 
and rFVIIIFc prophylaxis, so used unadjusted indirect com-
parisons within the model (as adjustment was not considered 
possible because of the small number of patients enrolled 
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Fig. 1  Model overview (schematic and determination of outcomes). 
TJ target joint
Table 1  Annualized bleeding rates used within the model [26, 31, 49]
Due to reporting limitations, mean ABRs (3.25 and 2.90) were 
applied for the adult population and median ABRs (4.00 and 1.96) 
were applied for the pediatric population. While these measures differ 
by group, consistent measures were applied within populations
ABR annualized bleeding rate, rFVIII recombinant Factor VIII, rFVI-
IIFc recombinant Factor VIII Fc fusion protein
Treatment rFVIII rFVIIIFc
Adult ABR 3.25 2.90
Pediatric ABR 4.00 1.96
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were explored within sensitivity analysis to ascertain the 
impact of ABRs on cost-effectiveness results.
For joint-related outcomes, annual probabilities of devel-
oping or resolving TJs were applied for patients treated with 
rFVIII and rFVIIIFc. Sensitivity analyses were conducted 
to ascertain the impact on results of alternative assumptions 
regarding joint-related health.
For rFVIIIFc, the probability of TJ resolution was calcu-
lated as 99.18% based on data from the A-LONG (n = 233 
of 235 resolved) and Kids A-LONG (n = 9 of 9 resolved) 
clinical trials [19, 33]. Data for the development of TJs 
were not available; however, given the high probability of 
TJ resolution, we assumed that no patients developed TJs 
while receiving rFVIIIFc. Recently available data from the 
A-LONG and Kids A-LONG studies showed that 95% and 
100%, respectively, of TJs with ≥ 6 months of follow-up 
post-resolution showed no TJ reoccurrence [34]. Therefore, 
we conducted a scenario analysis wherein the probability of 
TJ development was assumed to be equal to the proportion 
of TJs that showed no reoccurrence. However, it should be 
noted that this scenario assumed that TJ reoccurrence was 
equivalent to the probability of patients developing a TJ and 
so should be interpreted with caution.
For rFVIII, the probability of TJ resolution was assumed 
to be 73.33% based on a study by Panicker et  al. [35], 
wherein 11 of the 15 patients with TJs at baseline had no 
further TJ bleeds (with a minimum follow-up of 1 year). The 
study by Panicker et al. [35] was the only study identified by 
the authors that contained sufficient information to quantify 
the development of TJs for patients treated with prophy-
laxis. The probability of TJ development was estimated at 
9.87% based on a study by Kern et al. [24] in which 15 
of 16 boys developed at least one TJ while receiving epi-
sodic SHL rFVIII treatment over a 20-year period, adjusted 
according to the ratio of TJ-related bleeds observed in a 
study of once-daily and prophylaxis SHL rFVIII treatment 
by Manco-Johnson et al. [36].
2.2.2  Dosing
To determine the total weekly consumption of rFVIII per 
kilogram of body weight, the average dose per adminis-
tration was multiplied by the frequency of administration 
per week. The average dose of rFVIII per administration 
and every-other-day dosing was applied based on a study 
by Valentino et al. [31] for adults and one by Blanchette 
et al. [32] for pediatrics. In the model base case, average 
weekly doses of 109.75 IU/kg for adults and 107.30 IU/
kg−1 for pediatrics were applied. Pediatric dosing was 
applied within the model until 12 years of age (per the 
license for rFVIIIFc) [33].
For rFVIIIFc, the average reduction in weekly factor 
consumption versus conventional SHL rFVIII is reported 
in a range of published studies, identified via a targeted 
search of conference websites and the  MEDLINE® In-
Process (using PubMed.com) electronic database [37–41]. 
A random effects meta-analysis of real-world data con-
cerning the reduction in weekly factor consumption after 
switching from conventional rFVIII therapy to rFVIIIFc 
was performed. The results of the meta-analysis are pre-
sented in a forest plot (Fig. 2) and indicate a percentage 
reduction in Factor consumption of 21.8%.
Fig. 2  Meta-analysis of real-world dosing. Meta-analysis produced 
using the R package metafor. Sampling variance values  (vi) were not 
reported in all studies, and so were assumed to be equal to 20% of 
the mean divided by the square root of the sample size (i.e., a smaller 
study is associated with a larger variance). CI confidence interval
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In the model base case, the reduction in weekly factor 
consumption derived via the meta-analysis was applied for 
patients treated with rFVIIIFc versus rFVIII. Sensitivity anal-
yses were conducted within the model to quantify the impact 
on model results of alternative relative dosing settings.
Age-specific weight data for the US HA population 
were identified from the recent review of emicizumab for 
SHA patients with inhibitors by the Institute for Clini-
cal and Economic Review [42]. These data were adjusted 
using a calculated ratio of mean body weight between 
males from Italy and the USA of 0.92 to estimate the total 
Factor consumption of Italian SHA patients per year, and 
we assumed that weight data were comparable between 
the inhibitor and non-inhibitor populations [43]. Weight 
data were available only in 5-year intervals, so weight 
was assumed to be constant between age bands (e.g., 
ages 15–19). In sensitivity analysis, the use of unadjusted 
weight data for the US HA population was explored.
To resolve a bleeding episode, FVIII is required in addi-
tion to routine prophylaxis treatment. The use of rFVIII for 
breakthrough bleeding may require multiple infusions to 
successfully stop the bleeding, and—like prophylaxis—the 
dose required is based on patient body weight. Product 
consumption per year related to breakthrough bleeds was 
estimated using the following equation.
A summary of the data used to inform the economic 
model is provided as electronic supplementary material.
2.2.3  Health‑Related Quality of Life
The factors affecting patient utility captured within the 
model were the presence of TJs and the number of bleeds 
experienced.
Utility values for SHA patients with and without TJs were 
applied within the model based on a multivariate Poisson 
regression analysis by O’Hara et al. [5]. The regression analy-
sis provided estimated three-level EQ-5D (EQ-5D-3L) scores 
for patients with severe hemophilia and included covariates 
for the presence of TJs, age, and country (including Italy).
Each bleeding event was assumed to be associated with 
reduced HRQoL. Neufeld et al. [44] reported average utility 
scores for patients on a “bleed day” (0.660) and a “non-bleed 
day” (0.820). Assuming the duration of the impact of a bleed 
on utility is estimable, the number of QALYs lost per bleed 
may be calculated using the following equation.
FVIII use (IU) = ABR × Infusions per bleed
× Dose per infusion (IUkg−1) × Weight (kg).
QALYs lost =
Bleed impact duration (days)
Days in a year
×
(
UtilityNon - bleed day − UtilityBleed day
)
.
Published literature suggests that a bleeding episode 
may last for anywhere between 1 and 509 h [45]. However, 
the average duration over which a bleeding episode has an 
impact on patient utility is unclear. In the model base case, 
we assumed the detrimental effects of a bleed applied for 
5 days based on clinical input and the published report by 
the Institute for Clinical and Economic Review in which 
the full impact of a bleed applied for 2 days and a “half 
impact” applied for the remainder of the weekly model 
cycle [42]. This assumption was explored in sensitivity 
analysis. To adjust the number of QALYs lost per bleed 
event according to age, Italian age-specific multipliers 
from Scalone et al. [46] were applied to the base number 
of QALYs lost per bleed event [46].
2.2.4  Costs
rFVIII and rFVIIIFc are available in fixed vial sizes, so 
patients are often administered excess rFVIII. While this 
excess rFVIII consumption is considered safe (and may 
reduce the risk of breakthrough bleeds), the dose received 
per administration is important to capture within the CEA. 
Consequently, the average dose per administration is 
rounded up to the nearest whole vial (reflecting the target 
dose plus excess consumption due to the vial sizes).
rFVIII (Advate) and rFVIIIFc (Elocta) are available in 
250 IU, 500 IU, 1000 IU, 2000 IU, and 3000 IU vials. Both 
are linearly priced at €0.65 per IU (based on tender prices 
as of May 2019) [47]. As shown via the meta-analysis 
(Fig. 2), the total weekly consumption used in practice 
is lower for rFVIIIFc than for rFVIII because of its EHL. 
Costs were included based on the 2019 cost year.
2.2.5  Mortality
Tagliaferri et al. [48] conducted a retrospective cohort study 
to investigate mortality and causes of death in Italian peo-
ple with hemophilia between 1990 and 2007. They found 
that the life expectancy of Italian hemophilia patients has 
increased over time, approaching that of the male general 
population. This finding was attributed in part to the reduc-
tion in plasma-derived FVIII use, which historically was 
associated with patients contracting blood-related illnesses 
such as hepatitis C and HIV (the latter of which accounted 
for 60% of Italian hemophilia patient deaths between 1990 
and 1999) [48].
Within the CEA, general population mortality was 
assumed to apply for Italian SHA patients, so no bleed event 
was assumed to be fatal. Consequently, the CEA may have 
underestimated the full benefits of treatment that reduces the 
rate of bleeding; however, the proportion of bleeds that are 
fatal is expected to be very small.
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2.3  Model Outcomes
The primary outcome of the CEA was the cost per QALY 
gained (i.e., the incremental cost-effectiveness ratio [ICER]) 
from the health sector perspective over a lifetime horizon. 
Sensitivity analysis were conducted to test the robustness of 
the base-case cost-effectiveness results by exploring assump-
tions involving efficacy, dosing, and treatment benefit.
3  Results
3.1  Base-Case Results
The base-case results of the CEA are presented in Table 2. 
Compared with rFVIII, rFVIIIFc provided more QALYs 
at a reduced cost (i.e., rFVIIIFc dominates rFVIII). The 
reduction in costs was primarily attributable to the modelled 
reduction in weekly Factor consumption, and the difference 
in QALYs was largely related to the modelled resolution 
of TJs. Patients treated with rFVIII gained more QALYs in 
the “with TJs” health state than patients treated with rFVII-
IFc, as rFVIII was associated with larger probabilities of TJ 
development and non-resolution.
3.2  Sensitivity Analyses
Scenario analyses were conducted to explore the impact of 
alternative settings, assumptions, and data sources applied 
within the CEA. The results of these scenarios are pre-
sented in Table 3 and discussed in turn in the following. 
Table 2  Base-case results
ICER incremental cost-effectiveness ratio (i.e., cost per QALY gained), QALY quality-adjusted life-year, 
rFVIII recombinant Factor VIII, rFVIIIFc recombinant Factor VIII Fc fusion protein, TJ target joint
Base-case results rFVIII rFVIIIFc Incremental
Costs for prophylaxis use (€) 6,024,000 4,723,000 − 1,301,000
Costs for resolution of breakthrough bleeding (€) 132,000 108,000 − 25,000
Total costs (€) 6,157,000 4,831,000 − 1,326,000
QALYs gained in “with TJs” health state 3.11 0.31 − 2.80
QALYs gained in “without TJs” health state 22.60 25.74 3.14
QALYs lost due to bleeds 0.20 0.15 0.05
Total QALYs 25.51 25.90 0.39
ICER rFVIIIFc dominates
Table 3  Scenario analysis results
ABR annualized bleeding rate, ICER incremental cost-effectiveness ratio (i.e., cost per QALY gained), ITC indirect treatment comparison, QALY 
quality-adjusted life-year, rFVIII recombinant Factor VIII, rFVIIIFc recombinant Factor VIII Fc fusion protein, TJ target joint
a Base-case assumptions are as follows: use ABRs from pivotal studies, bleed impact = 5 days, time horizon = 99 years, TJ resolution included 
based on available data, dose reduction derived via meta-analysis of real-world data, weight data adjusted to reflect Italian population
Description rFVIII rFVIIIFc ICER
Costs (€) QALYs Costs (€) QALYs
Base  casea 6,157,000 25.51 4,831,000 25.90 rFVIIIFc dominates
1 Use ABRs from ITC 6,209,000 25.45 4,831,000 25.90 rFVIIIFc dominates
2 Use ABRs from ASPIRE 6,157,000 25.51 4,795,000 25.94 rFVIIIFc dominates
3 Bleed impact = 2 days 6,157,000 25.63 4,831,000 25.99 rFVIIIFc dominates
4 Bleed impact = 7 days 6,179,000 25.43 5,369,000 25.83 rFVIIIFc dominates
5 Time horizon = 30 years 3,745,000 19.21 2,946,000 19.49 rFVIIIFc dominates
6 Time horizon = 70 years 6,125,000 25.43 4,806,000 25.82 rFVIIIFc dominates
7 No TJ resolution (both arms) 6,157,000 23.30 4,831,000 24.02 rFVIIIFc dominates
8 Immediate TJ resolution (both arms) 6,157,000 25.60 4,831,000 25.90 rFVIIIFc dominates
9 TJ development 9.87% (both arms) 6,157,000 25.51 4,831,000 25.65 rFVIIIFc dominates
10 TJ development per reoccurrence (rFVIIIFc) 6,157,000 25.51 4,831,000 25.80 rFVIIIFc dominates
11 Dose reduction derived via ITC 6,157,000 25.51 5,149,000 25.90 rFVIIIFc dominates
12 US weight data 6,621,000 25.51 5,141,000 25.90 rFVIIIFc dominates
139Cost Effectiveness of rFVIIIFc for Hemophilia A
Probabilistic sensitivity analysis (PSA) was also conducted; 
however, in practice, many of the model parameters will be 
correlated (e.g., ABRs, Factor consumption, probability of 
TJ development, etc.). It was not possible to quantify the 
correlation between these key parameters. Furthermore, the 
structural assumptions underpinning the CEA (e.g., the use 
of TJ-based health states; sources of efficacy data) were con-
sidered more relevant than parameter uncertainty to assess 
the robustness of the base-case CEA results. Consequently, 
while PSA was conducted, it does not account for the cor-
relation between parameters (as no data are available), or the 
structural uncertainty, and should therefore be interpreted 
with caution. The results of the PSA are provided as Elec-
tronic Supplementary Material.
The impact of alternative ABRs on the CEA results 
was explored by using values reported in an indirect treat-
ment comparison (ITC) conducted by Iorio et  al. [49] 
(scenario 1) and the ASPIRE extension study of rFVIIIFc 
(NCT01454739) (scenario 2) [50]. In the ITC scenario, adult 
ABRs of 4.85 and 2.90 were applied for rFVIII and rFVII-
IFc, respectively (pediatric ABRs were unchanged). In the 
ASPIRE scenario, ABRs of 1.80 and 1.81 were applied for 
adult and pediatric patients treated with rFVIIIFc, respec-
tively (values for rFVIII remained per the base case). The 
results of the sensitivity analyses assuming alternative ABR 
values were very similar to the base-case results.
In the CEA base case, the impact of a bleed on patient 
utility was assumed to apply for 5 days. Sensitivity analysis 
explored the impact of reducing this to 2 days (scenario 3), 
and increasing it to 7 days, per the setting in the Henry et al. 
[22] CEA (scenario 4). As expected, reducing the duration 
of bleed impact caused a reduction in the incremental QALY 
gain associated with rFVIIIFc (and vice versa for the 7-day 
scenario), though the overall conclusion that rFVIIIFc domi-
nates rFVIII remained unchanged.
Italian pharmacoeconomic guidelines suggest that life-
time horizon calculations should be limited to a duration 
of 30 years. However, given the starting age of the cohort 
of 1 year, the base-case analysis adopts a much longer time 
horizon (99 years) such that all patients have died by the 
end of the modelled time horizon. Henry et al. [22] con-
sidered a 70-year time horizon. Sensitivity analysis results 
assuming shorter time horizons of 30 years (scenario 5) and 
70 years (scenario 6) provided lower estimates of total costs 
and QALYs across both treatment arms, with a consistent 
conclusion of rFVIIIFc dominating rFVIII per the model 
base case.
Given the limited data available regarding the resolution 
of TJs, sensitivity analysis was performed to establish the 
impact of assuming either no TJ resolution (0% probability) 
from baseline for both treatment arms (scenario 7), complete 
TJ resolution (100% probability) within the first year for 
both treatment arms (scenario 8), or the same probability 
of TJ development (9.87% probability) for both treatments 
(scenario 9). An additional scenario analysis was undertaken 
using recently published data regarding the proportion of 
reoccurring TJs observed within the A-LONG and Kids 
A-LONG studies as a proxy for TJ development in patients 
treated with rFVIIIFc (scenario 10) [34]. The results of 
these analyses illustrate consistent CEA results even when 
the probability of TJ resolution is varied to extreme values.
Two dosing-based sensitivity analyses were also con-
ducted. The first considered the use of dosing data per the 
studies included within the ITC by Iorio et al. [49] (i.e., 
excluding the real-world evidence) (scenario 11). The sec-
ond analysis considered the use of unadjusted weight data 
from the US hemophilia population (i.e., removal of the ratio 
to adjust US data to reflect the Italian population) (scenario 
12). Higher costs were noted for patients treated with rFVII-
IFc in both sensitivity analyses compared with the base case, 
though rFVIIIFc continued to dominate rFVIII.
Finally, a threshold analysis was conducted to ascertain 
what the per-unit cost of rFVIIIFc would need to be such 
that the total incremental costs were zero (i.e., rFVIIIFc was 
no longer cost saving). The result of this analysis was that 
rFVIIIFc would need to be at least €0.83 per IU for the total 
incremental costs to exceed zero.
4  Discussion
This study presents the findings of a CEA comparing the 
EHL rFVIII product rFVIIIFc with conventional SHL rFVIII 
for patients with SHA. The CEA adopted a lifetime horizon 
and incorporated prophylaxis and bleed-related Factor con-
sumption as well as the impact of bleeding and impaired 
joint health on patient utility. Real-world evidence regard-
ing Factor use was also included to facilitate a true-to-life 
estimation of Factor consumption in clinical practice. The 
base-case results of the CEA demonstrated that rFVII-
IFc dominated (provided more QALYs at a reduced cost) 
rFVIII because of a modelled lower frequency of bleeding, 
improved joint health, and reduced Factor consumption.
A range of sensitivity analyses were conducted to explore 
the impact of varying assumptions, data sources, and set-
tings on the CEA results. The overall conclusion remained 
unchanged across all scenarios explored, though costs were 
shown to be most sensitive to different model time hori-
zons and dosing assumptions (given that these scenarios had 
the greatest impact on the estimation of Factor consump-
tion costs). The incremental QALY gain for rFVIIIFc was 
consistently greater than zero, even when the impact of TJ 
resolution was omitted from the CEA.
These CEA results are aligned with the previous CEA 
of rFVIIIFc versus conventional factor therapies by Henry 
et al. [22]. In this study, the authors also demonstrated that 
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rFVIIIFc dominated a pooled comparator of SHL rFVIII 
therapies in the Swedish setting. However, as previously dis-
cussed, the authors were not able to quantify the impact of 
joint deterioration because published evidence was lacking 
when the study was conducted. The consistent findings of 
both CEAs support the use of rFVIIIFc in clinical practice.
While the incorporation of TJ-based health states within 
the CEA permitted the inclusion of joint health-related util-
ity values, it is noted that the model structure was limited 
to the presence or absence of at least one TJ (and does not 
distinguish between those with multiple TJs). O’Hara et al. 
[5] demonstrated within their analysis that the presence of 
multiple TJs was associated with increasingly impaired util-
ity. The use of dichotomous TJ-based health states was based 
on currently available data to inform the development and/or 
resolution of TJs and is aligned with a CEA in hemophilia B 
by van Keep et al. [51].
Further research regarding the long-term probabilities of 
developing and/or resolving TJs is required to validate the 
findings of this study. The AHEAD study (NCT02078427) 
is an ongoing observational study designed to document 
the natural history of HA [52]. The study is expected to 
complete in December 2019 and may provide data regard-
ing patient utility, bleed resolution, joint health outcomes, 
the development of inhibitors, and the incidence of new TJs 
[52].
The costs captured within the CEA are related entirely to 
the consumption of Factor product—either as prophylaxis 
or to treat breakthrough bleeding. We acknowledge that sev-
eral other direct medical costs are incurred by patients with 
SHA in Italy, including emergency hospital admissions for 
severe bleeding episodes and routine monitoring appoint-
ments with a hematologist. Data to inform the estimation of 
non-Factor costs were unavailable for the CEA. However, 
omission of these costs from the study is not expected to 
drastically alter the findings, as the reduction in ABR for 
rFVIIIFc versus rFVIII is expected to lead to reduced medi-
cal resource utilization.
We also note that pricing of rFVIII products in Italy is 
based on a tender market. That is, static list prices do not 
reflect the cost of each product, and the “true” prices of 
each product are updated periodically. Our study aims to 
address fluctuations in pricing for rFVIII products through 
the presentation of a sensitivity analysis regarding the price 
of rFVIIIFc, yet we note that such fluctuations may influence 
the usage of different rFVIII products in Italy and therefore 
influence the likely cost effectiveness of rFVIIIFc versus 
SHL rFVIII.
An additional consideration is that, over time, SHA 
patients may develop an immune response to rFVIII prod-
ucts in the form of inhibitor antibodies. In most cases, 
patients are able to resolve their inhibitors through a regimen 
of immune-tolerance induction (ITI) therapy with rFVIII 
treatment. The development of inhibitors was not captured 
within the CEA structure. Further research is required to 
understand the clinical and economic implications of using 
EHL rFVIII therapies (such as rFVIIIFc) with respect to the 
development of inhibitors.
The CEA also did not capture the impact of SHA on 
patient caregivers in terms of both costs and health effects. 
Kodra et al. [7] found that 21 of the 89 Italian hemophilia 
patients surveyed required a carer. The authors also deter-
mined an average loss of earnings for caregivers of children 
with hemophilia amounting to €4099.70 per year, though 
how improved care may affect this figure is unclear. The 
impact on caregivers and family members further demon-
strates the importance of effective treatment options for 
patients with SHA.
5  Conclusions
This study constitutes the first CEA in SHA to utilize 
recently published data regarding joint health and real-
world dosing to establish the long-term cost effectiveness 
of rFVIIIFc versus conventional (SHL) rFVIII therapy in the 
Italian setting. The model structure adopted within this CEA 
is the first in SHA to distinguish between patients according 
to the absence or presence of TJs. Our results demonstrate 
that rFVIIIFc provides a cost-effective treatment option ver-
sus SHL rFVIII treatments based on the improved bleed-
ing- and joint-related treatment outcomes predicted by the 
model (as well as reduced burden of administration because 
of its EHL). Further research is required to more accurately 
determine the relative improvement of rFVIIIFc versus SHL 
rFVIII treatments in terms of overall joint health.
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